Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 7/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.42 |
| ▸ | HTR1F | P30939 | 1/20 | 0.42 |
| ▸ | TYK2 | P29597 | 6/20 | 0.41 |
| ▸ | JAK1 | P23458 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30511719 | 1.00 | MAP3K5 (0.54) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL26599153 | 0.89 | TYK2 (0.51) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL31185798 | 0.89 | TYK2 (0.51) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL26599338 | 0.88 | TYK2 (0.47) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL31185868 | 0.88 | TYK2 (0.47) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL26599329 | 0.88 | TYK2 (0.47) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL31167992 | 0.84 | MAP3K5 (0.44) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL21329796 | 0.80 | TYK2 (0.52) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL25437185 | 0.78 | TYK2 (0.40) | MAP3K5HTR1AHTR1DHTR1FTYK2 | |
| SCHEMBL21330074 | 0.78 | L3MBTL1 (0.41) | MAP3K5HTR1AHTR1DHTR1FTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| WO-2024240062-A1 | PYRIDINE-PYRROLO DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-11-28 | — | — | WO | disclosed |
| WO-2024193689-A1 | PYRIDINOPYRROLE DERIVATIVE AND USE THEREOF IN DRUGS | 广东东阳光药业股份有限公司 | 2024-09-26 | — | — | WO | disclosed |
| CN-117043162-A | TYK2 selective inhibitors and uses thereof | 迈巴制药(南京)有限公司 | 2023-11-10 | — | — | CN | disclosed |
| WO-2023116748-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 广东东阳光药业有限公司 | 2023-06-29 | — | — | WO | disclosed |
| CN-116332961-A | Substituted heteroaryl compounds, compositions and uses thereof | 广东东阳光药业有限公司 | 2023-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051360-A1 | SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | TYK2, JAK2, JAK1 | MAP3K5 79/4885HTR1A 1952/4885HTR1D 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.